Second Opinion is an independent expert consultation that includes a comprehensive review of medical records, the established diagnosis, diagnostic results, and the proposed treatment plan according to current international clinical guidelines and evidence-based medicine principles.

A second medical opinion is a widely accepted practice in modern healthcare, especially in oncology and hematology. It does not represent a lack of trust in the treating physician. Instead, it helps confirm the accuracy of the diagnosis, evaluate the proposed treatment strategy, consider possible alternative approaches, and support patients in making informed decisions about their further care.?

A Second Opinion may be helpful:

• after a new oncological or hematological diagnosis has been established;
• before starting specific anticancer treatment;
• in case of disease relapse or progression;
• when several treatment options are available;
• when there are doubts regarding the diagnosis or recommended treatment strategy;
• when evaluating eligibility for advanced treatment options or clinical trials.

To receive an expert review, please send your medical documents by email:

Segretariato.oncoroggero@hin.ch

LIST OF CONFERENCE PRESENTATIONS (poster and oral)

1. Roggero E, Pascarelia A, Zucca E, Paterlini A, Savio A, Pedrinis E, Cavalli F. Treatment of H. pylori infection in primary tow-grade gastric lymphoma of mucosa-associated lymphoid tissue. Annals of Oncology; 5 (supp]. 8): 2 (02), 1994.

2. Zucca E, Roggero E, Pinotti G, Cavalli F. Prognostic factors for non-Hodgkin's lymphomas: The International Index can predict survival also in subtypes other than large-cell lymphomas. Annals of Oncology; 5 (suppl. 8): 132 (0665), 1994.

3. Pinotti G, Zucca E, Roggero E, Pedrins E, Capella C, Venco A, Cavalli F. Mantle cell lymphoma: clinical features and prognostic factors in a retrospective study of 65 cases. Annals of Oncology, 5 (suppl. 8): 140 (P703), 1994.

4. Roggero E, Sessa C, Pampallona S, Regazzoni S, Ghielmini M, Marx B, Neuenschwander H, Pagani O, Cavalli F. Place of death of cancer patients and impact of home care services: Southern Switzerland, 1991-1993. Annals of Oncology, 5 (supp'. 8): 206 (PI 036), 1994.

5. Zucca E, Bertoni F, Bosshard G, Roggero E, Ceresa E, Sanna P, Pedrinis E, Cavalli F. Clinical significance of bcl-2 (MBR) /JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. Annals of Oncology; 7(10): 1023-1027, 1996.

6. Roggero E, Zucca E, Pinotti G, Pascarella A, Cavalli F. Antibiotic treatment in low-grade gastric MALT lymphoma: updated results of a multicenter study. Schweiz Med Wochenschr; Suppl 74/1) 126: 34S, 1996.

7. Zucca E, Bosshard G, Roggero E, Ceresa E, Caval[i F. Prognostic significance of Bcl-2 (mbr)/JH rearrangements in circulating B-cells of patients with diffuse targe cell lymphoma. Annals of Oncology; 7(5): 109, 1996.

8. Zucca E, Bosshard G, Bertoni F, Cazzaniga G, Roggero E, Capella C, Cavalli F, Biondi A. Analysis of DH regions indicates that development of gastric MALT lymphoma is antigen-dependent. Annals of Oncology; 7(5): 109, 1996.

9. Bertoni F, Bosshard G, Roggero E, Cavalli F, Zucca E. Prognostic value of Bcl-2(mbr)/J rearrangements detected in peripheral blood by polymerase chain reaction at diagnosis and during follow-up in follicular lymphoma. Annals of Oncology, 7(5): 112, 1996.

10. Martinelli G, Saletti PC, Peccatori F, Greco C, Zucca E, Thum P, Roggero E, Aapro M, Cavalli F. Sandwich chemotherapy (Vinblastine, Bleomycin, Methotrexate) and involved field radiotherapy for stage IIA Hodgkin's disease: an effective and safe regimen with limited toxicity. Annals of Oncology, 7(5): 114, 1996.

11. Zucca E, Bertoni F, Bosshard G, Cazzaniga G, Roggero E, Capella C, Pedrinis E, Cavalli F, Biondi A

Analysis of gastric MALT-Iymphoma by Allele-Specific-OIigonucIeotide polymerase chain reaction (ASO-PCR). Blood 88 (10, suppl.l)•. 67%, 1996.

12. Hiddemann W, Brittinger G, Tiemann M, Parwaresch R, Stein H, Lister AT, Norton A, Pittaluga S, de Wolf-Peeters C, van Hoof A, Coiffier B, Berger F, Kluin-Nelemanns H, van Krieken H, Kluin P, Cavalli F, Roggero E, Pedrinis E, Montserrat E, Piris MA, Unterhalt M. Clinical characteristics and response to chemotherapy of mantle cell lymphomas — results of a European survey. Blood 88 (10,suppl.1): 2683, 1996

13. Hiddemann W, Brittinger G, Tiemann M, Parwaresch R, Stein H, Lister AT, Norton A, Pittaluga S, de Wolf-Peeters C, van Hoof A, Coiffier B, Berger F, Kluin-Nelemanns H, van Krieken H, Kluin P, Cavalli F, Roggero E, Pedrinis E, Montserrat E, Piris MA, Unterhalt M. Presentation features and clinical course of mantle cell lymphomas — results of a European survey. Annals of Oncology, 7(3): 72, 1996.

14. Corti R, Beretta F, Ghielmini M, Roggero E, Chevili S, Pedrinis E, Cavalli F, Gallino A. T-Zell-Lymphom nach

Herztransplantation: ein aussergewöhnlicher Verlauf mit vorübergehender Remission nach Absetzen von Cyclosporin A. 20e Congres de Médecine Générale, Genéve, 1997.

15. Martinelli G, Zucca E, Roggero E, Ullrich B, Peccatori F, Zimatore M, Saletti PC, Cocorocchio E, Cavalli F. Clinical results of a new alternating regimen in patients with advanced Hodgkin's disease (HD). Proceedings ASCO; 16: 8a(27), 1997.

16. Roggero E, Zucca E, Bertoni F, Maggi N, Vaisangiacomo C, Piffaretti JC, Cavalli F. Prevalence of Helicobacter pylori and hepatitis C virus (HCV) infections in primary gastric and non-gastric non-Hodgkin's lymphomas (NHL). Blood; 90 (Suppl.l): 276b (3948), 1997.

17. Roggero E, Zucca E, Bertoni F, Bernier J, Cavalli F. Comparison of prognostic models for diffuse large B-cell lymphomas (DLCL): can ß2-microgIobu[in (ß2M) improve upon the International Prognostic Index (IPI)? Proceedings ASCO; 16: 20a (70), 1997.

18. Roggero E, Zucca E, Bertoni F, Maggi N, Valsangiacomo C, Piffaretti JC, Cavalli F. Hepatitis C virus (HCV) infection among non-Hodgkin's lymphoma (NHL) patients in southern Switzerland. Proceedings of "Lymphoma ... The next questions 1997': abstract 01, 1997.

19. Roggero E, Bertoni F, Cazzaniga G, Biondi A, Capella C, Pedrinis E, De Boni M, Barbazza R, Cavalli F, Zucca E.

Molecular analysis of the immunoglobulin heavy chain genes CDR3 in primary gastric mucosa-associated lymphoid tissue (MALT) B-cell lymphoma. Proceedings of the "Expression, maintenance and propagation of the genome", Arolla Workshop: 96, 1997.

20. Zucca E, Roggero E, Bet-toni F & Cavalli F. Gastric MALT lymphoma. Annals of Oncology; 9 (suppl. 4): 3 (12 0), 1998.

21. Bertoni F, Müllenbach R, Zucca E, Jones C, Roggero E, Cavalli F & Cotter F. Alumorph genotyping of low-grade extranodal marginal zone-B-cell lymphoma (MALT lymphoma). Annals of Oncology; 9 (suppl. 4): 109 (523 P), 1998.

22. Roggero E, Bieri S, Zucca E, Bertoni F, Pedrinis E, Bernier J & Cavalli F. Primary mediastinal diffuse large cell lymphoma (PMCL): the experience of the Servizio Oncologico Cantonale and Servizio di Radioterapia, Ospedale San Giovanni Bellinzona. Annals of Oncology, 9 (suppl. 4): 111-112 (536 P), 1998.

23. Bertoni E, Roggero F, Cavalli F & Zucca E. Patient-specific molecular analysis in extranodal marginal zone lymphoma (MZL). The European Journal of Cancer, 34 (suppl.2): S24 (OPI 14), 1998.

24. Bieri S, Roggero E, Zucca E, Bertoni F, Sanna P, Pedrinis E, Bernier J & Cavalli F. Primary mediastinal diffuse large cell lymphoma (PMCL): the experience of the Servizio di Radioterapia and the Servizio Oncologico Cantonale, Ospedale San Giovanni Bellinzona. International Journal of Radiation Oncology Biology Physics; 42 (suppl.): 343 (2231 1998.

25. Bieri S, Roggero E, Zucca E, Bertoni F, Bernier J & Cavalli F. Primary mediastinal diffuse large cell lymphoma (PMCL): the experience of the Servizio di Radioterapia and the Servizio Oncologico Cantonale, Ospedale San Giovanni Beltinzona. Radiotherapy and Oncology, 48 (suppl. 1): s19 (75), 1998.

26. De Boni M, de Bona M, Bellumat A, Zucca E, Bertoni F, Roggero E, Pedrinis E, Biondi A, Barbazza R & Cavalli F. Endoscopic ultrasonography and primary low-grade B-cell gastric MALT lymphoma. Digestion; 59 (suppl. 3): 191 (FoN01517), 1998.

27. De Boni M, Zucca E, Bet-toni F, Bellumat A, de Bona M, Roggero E, Pedrinis E, Biondi A, Barbazza R & Cavalli F. Antigen selection and possible autoreactive origin in gastric MALT B-cell lymphomas clones. Digestion; 59 (suppl. 3): 255 (FoN02180), 1998.

28. Zucca E, Bertoni F, Roggero E, Cazzaniga G, Biondi A, Capella C, Pedrinis E, Barbazza R, , Cavalli F, Bellumat A, Molaro M, de Bona M & De Boni M. Antigen selection and possible autoreactive origin in primary gastric mucosaassociated lymphoid tissue (MALT) B-cell lymphoma clones. Italian Journal of Gastroenterology and Hepatology; 30 (suppl. 2); Al 72 (195), 1998.

29. Bertoni F, Zucca E, Roggero E, Cazzaniga G, Biondi A, Capella C, Pedrinis E, Barbazza R, , Cavalli F, Bellumat A, Molaro M, de Bona M & De Boni M. Autoreactive clones in primary gastric mucosa associated lymphoid tissue (MALT) Bcell lymphoma. Italian Journal of Gastroenterology and Hepatology, 30 (suppl. 2); A181 (23), 1998.

30. Bieri S, Roggero E, Zucca E, Bertoni F, Pedrinis E, Bernier J & Cavalli F. Primary mediastinal diffuse large cell lymphoma (PMCL): the experience of the Servizio Oncologico Cantonale and Servizio di Radioterapia, Ospedale San Giovanni Beliinzona. Schweizerische Medizinische Wochenschrift; 128 (suppl. 98): 43S (R013), 1998.

31. Roggero E, Zucca E, Bertoni F, Luscieti P, Pedrinis E & Cavalli F. Low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma: the Servizio Oncologico Cantonale Ticinese experience. Schweizerische Medizinische Wochenschrift, 128 (suppl. 98): 43S (R016), 1998.

32. Zucca E, Bertoni F, Roggero E, Genini D, Cazzaniga G, Biondi A & Cavalli F. Pattern of kappa-deletion rearrangements in low-grade non-Hodgkin's lymphomas. Proceedings of the "B-Cell Lymphoproliferative Disorders: contributions of molecular and cell biology to understanding and treatment" conference, New York (USA): 2, 1998.

33. Cortelazzo S, Rossi A, Roggero E, Oldani F, Zucca E, Tondini C, Ambrosetti A, Pinotti G, Bertini M, Busetto M, Gianni L, Cavalli F, Barbui T for the International Extranodal Lymphoma Study Group (IELSG). International Prognostic Index (IPI) effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma.. Proceedings of the American Society of Haemato/ogy (ASH) , Blood; 92: 10 (suppr. 1 (part 1 of 2)): 2577, 1998.

34. Zucca E, Roggero E, Traulié C, Delchier JC, Smith P, Pedrinis E, Motta T, Capella C, Copie-Bergmann C,

Wotherspoon A, Souhami R for the International Extranodal Lymphoma Study Group (IELSG), the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and the United Kingdom Lymphoma Group (UKLG). Early interim report of the LY03 randomized cooperative trial of observation vs. Chlorambucil after anti-Helicobacter pylori therapy in low-grade gastric lymphoma. Annals of Oncology; 10 (suppl. 3): 25 (070), 1999.

35. Roggero E, Copie-Bergmann C, Traullé C, Delchier JC, Barbazza R, De Boni M, Pedrinis E, Zucca E. Regression of high grade B-cell gastric lymphoma after eradication of helicobacter pylori infection. Annals of Oncology; 10 (suppl. 3): 67 (P230), 1999.

36. Cortelazzo S, Rossi A, Roggero E, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pinotti G, Bertini M, Busetto M, Gianni L, Ferreri A, Martinelli G, Baldini L, Cavalli F, Barbui T for the International Extranodal Lymphomas Study Group (IELSG).

The International Prognostic Index (IPI) correlates to survival in patients with localized primary gastric diffuse large B-cell lymphoma (PGL). Annals of Oncology, 10 (suppl. 3): 68 (P231), 1999.

37. Zucca E, Bertoni F, Roggero E, Gisi M, Cavalli F. Patient-specific molecular monitoring of MALT-Iymphoma after antibiotic treatment. Proceedings ASCO; 18: 10a (*31), 1999.

38. Roggero E, De Boni M, Barbazza R, Copie-Bergmann C, Traullé C, Delchier JC, Pedrinis E, Zucca E. Regression of high grade B-cell gastric lymphoma after eradication of Helicobacter pylori infection. Gut, 45 (suppl.V): A24 (029.06), 1999.

39. Conconi A, Bertoni F, Roggero E, Pedrinis E, Motta T, Luminari S, Bonato M, Cavalli F, Zucca E. Monocytoid lymphomas may arise from different subsets of marginal zone B lymphocates. Proceedings ESMO, oral presentation, 2000.

40. Zucca E, Conconi A, Roggero E, Ascani S, Campo E, Capella C, Fraternali G, Giardini R, Ponzoni M, Pedrinis E. Non gastric MALT lymphomas: a survey of 369 European patients — The International Extranodal Lymphoma Study Group (IELSG). Proceedings ESMO, oral presentation, 2000.

41. Zucca E, Roggero E, Smith P, Traullé C, Copie-Bergmann C, Delchier JC, Souhami R, Cavalli F and Hancock BW for the IELSG, GELA an IJKLG. Gastric MALT lymphoma: response to anti-Helicobacter therapy in the ongoing LY03 randomised co-operative trial of observation vs Chlorambucil after anti-helicobacter therapy. Proceedings ASCO, oral presentation, 2000.

42. Zucca E and Roggero E. The seventh Lugano conference — basic science, translational and clinical research in the lymphoma field: the challenge goes on. Annals of Oncology, 11 (Suppl. 1): 1, 2000.

43. Conconi A, Bertoni F, Pedrinis E, Roggero. E, Motta T, Luminari S, Capella C., Bonato M, Cavalli F and Zucca E. Nodal marginal zone B-cell lymphomas display different patterns of heavy chain variable region genes mutations., Proceedings of the European Haematology Association (EHA), (P494), 2001.

44. Uhr M, Lucchini R, Pedrazzini A, Roggero E. Marginal zone B-cell lymphomas and secondary lymphoproliferative diseases: only coincidence? Proceedings of the American Society of Haematology (ASH) , Blood; 98: 1 1 (suppl. 2 (part 2 of 2)): 4666, 2001.

45. E. Roggero, G. Busi, A. Palumbo, A. Pedrazzini. Oral administration of gefitinib ('Iressa', ZDI 839) is active against brain metastases patient with non small cell lung cancer (NSCLC).

Poster presentation at Gemeinsame Jahrestagung der Deutschen Oesterreichischen und Schweizerischen gesellschaften für Hämatologie und Onkologie, Basel 4 — 8 Oktober 2003

46. A. Pedrazzini, G. Busi, A. Palumbo, E. Roggero. Multiple adverse events after a short time of gefitinib ('Iressa', ZDI 839) treatment. Abstract 121, ICE Meeting, Madrid Spain, June 28, 2003

47. E. Roggero, G. Busi, A. Palumbo et al. Experience with gefitinib ('Iressa', ZDI 839) at Oncologia Lago Maggiore, Switzerland. Abstract 122, ICE Meeting, Madrid Spain, June 28, 2003

48. E. Roggero, G. Busi, A. Palumbo et al. Stable disease after 5 months gefitinib ('Iressa', ZDI 839) intake. Abstract 128, ICE Meeting, Madrid Spain, June 28, 2003

49. E. Roggero, G. Busi, A. Palumbo et a}. Good response in primary tumour, brain, cerebellar and liver metastases after 2 months gefitinib ('tressa', ZD1839) treatment. Abstract 129, ICE Meeting, Madrid Spain, June 28, 2003

50. E. Roggero, G. Busi, A. Palumbo et al. Good response in primary tumour, brain, cerebellar and liver metastases after 2 months' gefitinib ('Iressa', ZDI 839) treatment. Supplement of the British Journal of Oncology Abstract 129, December 2003

51. E Roggero MDI , M De Boni MD3 , M Brambilla MD2, M. Imparato Staff, L. Artioli Staff, M Brambilla MD2 A. Moretti Stati , A Pedrazzini MDI , A. Pelloni MD I , R Barbazza MD2. Incidence reduction of Helicobacter Pylori infection during the past decade in the Feltre Region (Italy): influences on chronic gastritis, Malt lymphoma and gastric cancer.

Oral presentation by E. Roggero at 7th International Symposium on Predictive Oncology and Intervention Strategies, Nice, France February 7-10 2004

52. E Roggero MD I , M De Boni MD3, M Brambilla MD2 , M. imparato Staff, L. Artioli Staff, M Brambilla MD2 A. Moretti Stati , A Pedrazzini MD I , A. Pelloni MDI , R Barbazza MD2 . Incidence reduction of Helicobacter Pylori infection during the past decade in the Feltre Region (Italy): influences on chronic gastritis, Malt lymphoma and gastric cancer.

Poster presentation by E. Roggero at SGIM —Schweizerischen Gesellschaft für Innere Medizin- Lausanne May 13, 2004

53. E. Roggero, A. Palumbo, S. Di Martino, G. Busi, A. Pedrazzini: An Applicational Observatio of Low-Dose Rituximab in Elderly Patients with Nodal Marginal Zone Lymphomas. Blood 2005 106: Abstract 4771 ; November 2005

54. Borner M, Morant R, Rochlitz C, Schönenberger A, Pedrazzini A, Roggero E, Knuth A, Salzberg M. An Open-label phase Il trial to evaluate the efficacy and the safety of combining docetaxel with gefitinib in patients with metastatic hormone-refractory prostate cancer. Proceeding of the American Society of Clinical Oncology (ASCO) prostate cancer symposium; Poster presentation 2006.

55. Roggero E, Palumbo A, Cerny A, Giostra E, Majno P, Mazzucchelli L, Bonetti A, Pedrazzini A. Rituximab is active against post-transplant CNS lymphoma (PTCNSL). Proceedings of the European Haematology Association (EHA), (abs 341), 2007.

56. Roggero E, Palumbo A, Cerny A, Giostra E, Majno P, Mazzucchelli L, Bonetti A, Pedrazzini A. Rituximab is active against post-transplant CNS lymphoma (PTCNSL). Poster presentation SGIM —Schweizerischen Gesellschaft für Innere Medizin- Basel 25 May, Schweiz Med Forum 7: (Suppl.35), PI 10, 2007.

57. Camerini L, Galli N, Boneschi M, Maniscalco C, Pedrazzini A, Roggero E. A patient driven design to develop an informative web platform on cancer topics. An on-field study in Tessin. Oral presentation at the Comet conference, Lugano 28-30 June, 2007.

58. Roggero E, Palumbo A, Pelloni A. Huber O, Biegger P, Pedrazzini A. Long-term survival of a patient with advanced duodenal solid cancer treated with neoadjuvant chemotherapy followed by surgical resection: a case report. Poster presentation SGIM —Schweizerischen Gesellschaft für Innere Medizin- Lausanne 21 May, Schweiz Med Forum: PI 33, 2008.

59. Roggero E, Palumbo A, Varini M, Calderoni A, Pedrazzini A. Cancer patients dying at home: the experience of the palliative care service of the Associazione Triangolo in Southern Switzerland. Poster presentation SGIM Schweizerischen Gesel/schaft für Innere Medizin — Basel 13 May, Schweiz Med Forum: PI 28, 2009.

60. Palumbo A, Roggero E, Varini M, Calderoni A, Pedrazzini A. Decesso a domicilio in pazienti oncologici: esperienza del servizio di cure palliative dell'Associazione Triangolo nella Svizzera meridionale. XVI Congresso nazionale societå italiana di cure palliative — Lecce, Ottobre 2009.

61. Roggero E, Busi G, Palumbo A. Pedrazzini A. Transitory cognitive disorders in cancer patients treated with sorafenib. Poster presentation SGIM — Schweizerischen Gese//schaft für Innere Medizin — Basel 19 May, Schweiz Med Forum: P32, 2010.

62. E Roggero, M Sarti, S Pinton, G.N Thalman, C.V Catapano, I.M Bonapace, G.M Carbone. Correlation of UHRFI expression in primary prostate cancer patients with adverse prognosis. Poster presentation at ASCO meeting: Abstract no. 4661, Journal of Clinical Oncology 30, 2012.

63. Stanta G, Barbazza R, Roggero E, Marchesin F, Pracella D, Bonin S. HPV E7 monoclonal antibody may help to define better prognosis of prostate cancer. Oral presentation at "Global Congress on prostate cancer', Abstract 35, June 2012.

64. Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G, Thalman GN, Bonapace 1M, Catapano CV, Carbone GM. Nuovi biomarcatori nel carcinoma prostatico: ruolo del fattore epigenetico UHRFI nel definire il rischio di progressione di malattia. Seconda giornata di ricerca clinica della Svizzera Italiana, Abstract 57, marzo 2012

65. Roggero E, Sarti M, Pesce G, Stoffel F, Lladö A, Barbazza R, Stanta G, Cavalli F, Catapano CV, Carbone GM,

Alimonti A. Espressione degli oncosoppressori PTEN e P53 nei pazienti con carcinoma della prostata. Seconda giornata di ricerca clinica della Svizzera Italiana, Abstract 56, marzo 2012.

66. Roggero E, Sarti M, Pinton S, Thalmann G, Catapano C, Bonapace 1M, Carbone G. Correlation of UHRFI expression in primary prostate cancer patients with adverse prognosis. J Clin Oncol 30, 2012 (suppl; abstr 4661 )

68. Stanta G, Barbazza R, Roggero E, Marchesin F, Pracella D, Bonin S. HPV E7 monoclonal antibody may help to define better prognosis of prostate cancer. Oral presentation at "Global Congress on prostate cancer', Abstract 35, June 2012.

69. Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G, Thalman GN, Bonapace 1M, Catapano CV, Carbone GM. Nuovi biomarcatori net carcinoma prostatico: ruolo del fattore epigenetico UHRFI nel definire il rischio di progressione di malattia. Seconda giornata di ricerca clinica della Svizzera Italiana, Abstract 57, marzo 2012

70. Stanta G, Barbazza R, Prace\la D, Sulfaro S, Pascale M, Marongiu B, Roggero E, Bonin S. Poster "1 1 virus del papiltoma umano nel carcinoma della prostata". Terza giornata della ricerca clinica della Svizzera italiana, Lugano, Switzerland, 22 marzo 2013.

71. Stoffel F, Mazzola B, Peyer P, Pesce G, Azinwi NC, Llado' A, Wyttenbach R, Puligheddu C, Crippa S, Bordoni A, Bianchi Galdj V, Sarti M, Marongiu B, Pasca[e M, Roggero E. Presentazione orale flash: Uroboard EOC, un approccio multidisciplinare nel trattamento dei pazienti con neoplasie urogenitali. Terza giornata della ricerca clinica della Svizzera italiana, Lugano, Switzerland, 22 marzo 2013

72. Giurgiu l, Pascale M, Azinwi C, Marongiu B, Pittoni P, Picardi C, Martucci F, Valli MC, Richetti A, Roggero E, Pesce G. Poster. "Single Institution Analysis of Pelvic Radiotherapy for High Risk Prostate Cancer'. 17th Annual SASRO "Scientific Association of Swiss Radiation Oncology" Meeting, Davos, Switzerland, July 4-6, 2013.

73. Azjnwi NC, Stoffel F, Mazzola B, Peyer P, Llado' A, Puligheddu C, Crippa S, Bordoni A, Bianchi V, Marongiu B, Pascale M, Roggero E, Richetti A, Wyttenbach R, Pesce G. Poster. "The EOC Uroboard, a multidisciplinary approach to the management of patients with urogenital cancefl'. 17th Annual SASRO "Scientific Association of Swiss Radiation Oncotogy" Meeting, Davos, Switzerland, Juty 4-6, 2013.

74. Pascale M, Marongiu B, Wyttenbach R, Crippa S, Treglia G, Llado' A, Mazzola B, Pesce G, Stoffel F, Roggero E. Poster e presentazione orale flash: "Studio di paragone per valutare l'impatto della discussione multidisciplinare sul trattamento del carcinoma della prostata". Quarta giornata della ricerca clinica della Svizzera italiana, Bellinzona, Switzerland, 28 marzo 2014.

75. Pascale M, Marongiu B, Llado' A, Pesce G, Stoffel F, Roggero E. Poster. "Carcinoma della prostata con basso PSA alla diagnosi: alto rischio di metastasi viscerali?" Quarta giornata della ricerca clinica della Svizzera italiana, Bellinzona, Switzerland, 28 marzo 2014.

76. Pascale M, Marongiu B, Pesce G, Barizzi J, Wyttenbach, Treglia G, Bordoni A, Stoffel F, Roggero E, a nome dei partecipanti all'Uroboard. Gestione multidisciplinare dei pazienti con tumori urogenitali presso l'ente ospedaliero cantonale. Tribuna Medica Ticinese, 2014: 79: 245-8.

77. Mazzola B, Pollorsi G, Pascale M, Marongiu B, Pesce G, Roggero E, Stoffel F. Poster e presentazione orale flash: "Analisi preliminare dell'esito oncologico della prostatectomia radicale in laparoscopia robot-assistita presso I'EOC". Quinta giornata della ricerca clinica della Svizzera italiana, Lugano, Switzerland, 27 febbraio 2015.

78. Pascale M, Bonin S, Marongiu B, Barbazza R, Stanta G, Roggero E. Poster: "Analisi preliminare sul ruolo dell'espressione neuroendocrina nel Carcinoma della Prostata (CaP)". Quinta giornata della ricerca clinica della Svizzera italiana, Lugano, Switzerland, 27 febbraio 2015.

79. Pascale M., Marongiu B., Pesce G., Stoffel F., Roggero E. Presentazione orale flash: Progressione metastatica in una coorte di pazienti con carcinoma della prostata trattati con intento curativo. Sesta giornata della ricerca clinica della Svizzera italiana, Palazzo dei congressi, Lugano, Switzerland, 18 marzo 2016.

80. Pascale M., Azinwi C., Pesce G., Roggero E., Stoffel F., Richetti A. Presentazione orale: Impact of the site of metastasis on prostate cancer-specific survival in patients treated with curative radiotherapy. 20th Annual SASRO "Scientific Association of Swiss Radiation Oncology" Meeting, Sursee, Switzerland, August 25-27, 2016.

81. Pascale M., Puligheddu C., Barizzi J., Mazzola B., Stoffel F., Wyttenbach R., Roggero E. Presentazione orale: Accuratezza diagnostica della Risonanza Magnetica prostatica preoperatoria nei pazienti sottoposti a prostatectomia radicale laparoscopica robot-assistita. Settima giornata della ricerca clinica della Svizzera italiana, Università della Svizzera Italiana, Lugano, Switzerland, 10 marzo 2017.

LIST OF PUBLICATIONS (PEER REVIEWED)

1. Roggero E, Stricker H, Biegger P. Severe accidental hypothermia with cardiopulmonary arrest: prolonged resuscitation without extracorporeal circulation. Schweiz. Med Wochenschr, 122: 161-164, 1992.

2. Roggero E, Zucca E, Cavalli F. Primary gastrointestinal lymphoma: clinical aspects and diagnostic criteria. Schweiz. Med Wochenschr. 1993.

3. Zucca E, Fontana S, Roggero E, Pedrinis E, Pampa[lona S, Cavalli F. Treatment and prognosis of centrocytic (Mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution. Leukemia & Lymphoma; 13: 105-110, 1994.

4. Zucca E, Roggero E, Pinotti G, Pedrinis E, Capella C, Venco A, Cavalli F. Patterns of survival in Mantle cell lymphoma. Annals of Oncology; 6: 257-262, 1995.

5. Roggero E, Zucca E, Pinotti G, Pascarella A, Capella C, Savio A, Pedrinis E, Paterlini A, Venco A, Cavalli F. Eradication of Helicobacter-pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med; 122: 767-769, 1995.

6. Zucca E, Pinotti G, Roggero E, Comi MA, Pascarella A, Capella C, Pedrinis E, Cavalli F.

High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma. Annals of Oncology, 6: 726-728, 1995.

7. Zucca E, Bertoni F, Bosshard G, Roggero E, Ceresa E, Sanna P, Pedrinis E, Cavalli F. Clinical significance of bcl-2 (MBR) /JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. Annals of Oncology, 7(10): 1023-1027, 1996.

8. Zucca E, Roggero E. Biology and treatment of MALT lymphoma: the state of the art in 1996. A workshop at the 6th International Conference on Malignant Lymphoma. Annals of Oncology, 7: 787-792, 1996

9. Cavalli F, Roggero E, Zucca E. Treatment of gastric MALT lymphoma. Annals of Oncology; 7(3): 3, 1996.

10. Sessa C, Roggero E, Pampallona S, Regazzoni S, Ghielmini M, Lang M, Marx B, Neuenschwander H, Pagani O, Vasiljevic V, Cavaili F. The last three months of life of cancer patients. Medical aspects and role of homecare services in southern Switzerland: Home care services for patients. Supp Care Cancer; 4: 180-185, 1996.

11. Zucca E, Roggero E, Cavalli F. Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphomas (Letter). Ann Intern Med , 124: 275-276, 1996.

12. Cavalli F, Roggero E, Zucca E. Treatment of gastric MALT lymphoma. Trends in onco-hematology, 4 (3): 56-57, 1996.

13. Martinelli G, Peccatori F, Ullrich B, Ghielmini M, Roggero E, Goldhirsch A. Clinical manifestation of severe hyperammonaemia in patients with multiple myeloma (Letter). Annals of Oncology; 8: 751-756, 1997.

14. Bertoni F, Cazzaniga G, Bosshard G, Roggero E, Barbazza R, De Boni M, Capella C, Pedrinis E, Cavalli F, Biondi A, Zucca E. Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B-cells have undergone an antigen selection process. Br J Haematol; 97: 830-836, 1997.

15. Zucca E, Roggero E, Bertoni F, Cavalii F. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Annals of Oncology, 8: 727-737, 1997.

16. Roggero E, Zucca E, Cavalli F. Gastric mucosa-associated lymphoid tissue lymphomas: more than a fascinating model. J Nat/ Cancer Inst; 89 (18): 1328-1330, 1997.

17. Pinotti G, Zucca E, Roggero E, Pascarella A, Bertoni F, Savio A, Savio E, Capelia C, Pedrinis E, Saletti pc, Morandi E, Santandrea G Cavalli F. Clinical features, treatment and outcome in a series of 93 patients with lowgrade gastric MALT lymphoma. Leukemia & Lymphoma; 26 (5-6): 527-537, 1997.

18. Sanna P, Bertoni F, Roggero E, Quattropani C, Rusca T, Pedrinis E, Monotti R, Mombelli G, Cavalli F, Zucca E. Angiotropic (intravascular) large cell lymphoma: case report and short discussion of the literature. Tumori; 83 (4): 772-775, 1997.

19. Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, Biondi A & Cavalli F. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to MALT lymphoma of the stomach. New England Journal of Medicine; 338: 804-810, 1998.

20. Zucca E, Bertoni F, Roggero E & Cavalli F. Management of rare forms of lymphomas. Current Opinion in Oncology, 10: 377-384, 1998.

21. Zucca E, Bertoni F, Roggero E, Cazzaniga G, Bosshard G, Biondi A & Cavalli F. Autoreactive B-cell clones in marginal-zone B-cell lymphoma (MALT lymphoma) of the stomach. Leukemia; 12: 247-249, 1998.

22. Bertoni F, Sanna P, Zucca E, Roggero E & Cavalli F. Primary extranodal lymphoma of skeletal muscles: a report of four cases and discussion of the literature. Oncology Reports; 5: 605-607, 1998.

23. Sanna P, Bertoni F, Zucca E, Roggero E, Passega Sidler E, Fiori G, Pedrinis E, Mombelli G & Cavalli F. Cardiac involvement in primary extranodal HIV-related lymphoma of the liver: a case report and short review of the literature. Annals of Haematology, 77: 75-78, 1998.

24. Roggero E, Bieri S, Zucca E, Bertoni F, Pedrinis E, Bernier J & Cavalli F. Primary mediastinal diffuse large cell lymphoma (PMCL): the experience of the Servizio Oncologico Cantonale and Servizio di Radioterapia, Ospedale San Giovanni Bellinzona. Annals of Oncology, 9 (suppl. 4): 111-112 (536 P), 1998.

25. Zucca E, Roggero E, Pileri S. B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumors. BrJ Haematol; 100: 1 3-14, 1998.

26. Zucca E, Roggero E, Cavalli F. Gastric MALT lymphomas, new insight and still unanswered questions. Ital J Gastroenterol Hepato/; 30: 1 5-9, 1998.

27. Siebert R, Matthiesen P, Harder S, Zhang Y, Borowski A, Zühlke-Jenisch R, Plendl H, Metzke S, Joos S, Zucca E, Weber-Mattiesen K, Roggero E, Grote W, Schlegelberger B. Application of interphase cytogenetics for the detection oft (1 1 ; 14) (q13; q32) in mantle cell lymphomas. Annals of Oncology; 9:5 519-26, 1998.

28. Bertoni F, Zucca E, Genini D, Cazzaniga G, Roggero E, Ghielmini M, Cavalli F, Biondi A. Immunoglobulin fight chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. Leukemia & Lymphoma; 36: 147-150, 1999.

29. Bieri S, Roggero E, Zucca E, Bertoni F, Pianca S, Sanna P, Pedrinis E, Bernier J & Cavalli F. Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective clinical trials. Leukemia and Lymphoma; 35: 537-544, 1999.

30. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 2: head and neck, central nervous system and other less common sites. Annals of Oncology; 10: 537-544, 1999.

31. Cortelazzo S, Rossi A, Roggero E, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pasini F, Pinotti G, Bertini M, Vitol,o U, Busetto M, Gianni L, Cavalli F, Barbui T for the International Extranodal Lymphomas Study Group (IELSG). International Prognostic Index predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. Annals of Oncology; 10: 1-8, 1999.

32. Furlan D, Bertoni F, Cerutti R, Taborelli M, Pinotti G, Roggero E, Cavalli F, Bonato M, Zucca E, Capella C. Microsatellite instabiiity in gastric MALT lymphomas and other associated neoplasms. Annals of Oncology; 1 0: 783-788, 1999.

33. Roggero E. More on cancer vaccine. Annals of Oncology, 10: 1-2, 1999.

34. Zucca E, Bertoni F, Roggero E, Gisi M, Cavalli F. Patient-specific molecular monitoring of MALT-Iymphoma after antibiotic treatment. Proceedings ASCO; 18: 10a (*31), 1999.

35. Zucca E, Roggero E, Maggi-Solcå N, Conconi A, Bertoni F, Reilly l, Castelli D, Pedrinis E, Piffaretti JC, Cavalli F. Prevalence of Helicobacter pylori and Hepatitis C Virus (HCV) infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica; 85: 147-153, 2000.

36. Zappa F, Roggero E, Bertoni F, Zucca E, Luminari G, Cavalli F, Gallino A, Pedrinis E. Withdrawal of immunosuppressive therapy induced transient regression of aggressive intestinal natural killer (NK)-like T-cell lymphoma raised in a heart-transplant recipient. European J Cancer, 2000.

37. Bertoni F, Conconi A, Roggero E, Sanna P, Pedrinis E, Cavalli F, Zucca E. Association of gastric and Waldeyer's ring lymphoma: a molecular study. Haematological oncology; 18: 15-19, 2000.

38. Bertoni F, Müllenbach R, Zucca E, Jones C, Roggero E, Cavalli F & Cotter F. ALU polymerase chain reaction genotyping of low-grade extranodal marginal zone-B-cell lymphoma (MALT lymphoma). Leukemia; 14: 446-448, 2000.

39. Bertoni F, Mullenbach R, Broggini M, Roggero E, Cavalli F, Cotter FE, Zucca E. Extranodal marginal zone B-cell lymphoma genotyping by Alu-poåymerase chain reaction. Leukemia Lymphoma; 38(5-6): 605-610. 2000.

40. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood; 96: 410419, 2000.

41. Zucca E, and Roggero E. The seventh Lugano conference — basic science, translational and clinical research in the lymphoma field: the challenge goes on. Annals of Oncology; 11 (Suppl. 1): 1, 2000.

42. Roggero E, Zucca E, Mainetti C, Bertoni F, Pedrinis E, Borisch B, Valsangiacomo C, Piffaretti JC, Cavalli F, Isaacson PG. Eradication of Borrelia Burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Human Pathology; 31 : 263-268, 2000.

43. Conconi A, Zucca E, Roggero E, Bertoni F, Bernasconi A, Mingrone W, Pedrinis E, Cavalli F. Prognostic models for diffuse large B-cell lymphoma. Hematol. Oncology, 18(2): 61-73, 2000.

44. Bertoni F, Gisi M, Roggero E, Conconi A, Mingrone W, Cavalli F, Zucca E. Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma. Dig. Liver Dist 32(3): 188-191 , 2000.

45. Zucca E., Roggero E., DelchierJC. Et al. Interim evaluation og gastric MALT lymphoma response to antibiotics in the ongoing LY03 randomised cooperative trial of observation vs chlorambucil after anti-Helicobacter therapy. Proc. Am soc Clin Oncol 2000; 19:5a.

46. Roggero E, Copie-Bergmann C, Traullé C, Delchier JC, Barbazza R, De Boni M, Pedrinjs E, Zucca E. Regression of high grade B-cell gastric lymphoma after eradication of helicobacter pylori infection. Annals of Oncology, 10 (suppl. 3): 67 (P230), 1999.

47. Roggero E, De Boni M, Barbazza R, Copie-Bergmann C, Traullé C, Delchier JC, Pedrinis E, Zucca E. Regression of high grade B-cell gastric lymphoma after eradication of Helicobacter pylori infection. Gut, 45 (suppl.V): A24 (029.06), 1999.

48. Cortelazzo S, Rossi A, Roggero E, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pinotti G, Bertini M, Busetto M,

Gianni L, Ferreri A, Martinelli G, Batdini L, Cavalli F, Barbui T for the International Extranodal Lymphomas Study Group OELSG). The International Prognostic Index (IPI) correlates to survival in patients with localized primary gastric diffuse large B-cell lymphoma (PGL). Annals of Oncology, 10 (suppl. 3): 68 (P231 ), 1999.

49. Conconi A, Bertoni F, Pedrinis E, Motta T, Roggero. E, Luminari S, Bonato M, Cavalli F and Zucca E. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood; 1; 2001.

50. Roggero E, Busi G. Palumbo A, Pedrazzini A. Gefitinib ("Iressa", ZD1839) is active against brain metastases in a 77-year-old patient. Journal of Neuro-OncoIogy 71 : 277-280, 2005

51. Salzberg M. Rochlitz C, Morant R, Thalmann G, Pedrazzini A, Roggero E, Schonenberger A, Borner M, An openlabel, non-comparative phase H trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer, Onko/ogie Jul 2007.

52. F. Babbo, C. Pistore, L. Curti, I Castigno[i, P. Kunderfranco, L. Brino, P.Oudet, R Seiler, GN Thalman, E Roggero, M Sarti, S Pinton, M Mello-Grand, G Chiorino, CV Catapano, GM Carbone and 1M Bonapace. The SRA protein UHRFI promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene (2012) 1-10, 2012.

53. The EOC Multidisciplinary Urogenital Tumor Board. Multidisciplinary management of urogenital tumors at the Ente Ospedaliero Cantonale. Schweizer Krebsbulletin, 2013; 4: 315-8.

54. Pascale M, Pracella D} Barbazza R, Marongiu B, Roggero E, Bonin S, Stanta G. Is human papillomavirus associated with prostate cancer survival? Disease Markers, 2013; 35:607-13.

55. Pascale M, Marongiu B, Stoffel F, Pesce G, Llado' A, Barizzi J, Wyttenbach R, Treglia G, Mazzola B, Azinwi NC, Puligheddu C, Paone G, Bordoni A, Mazzucchelli L, Roggero E, on behalf of Uroboard's participants.

Multidisciplinary urogenital tumor board at a multisite hospital in the South of Switzerland: impact on disease management and clinical research. (submitted).

56. Pascale M, Aversa C, Barbazza R, Marongiu B, Siracusano S, Stoffel F, Sulfaro S, Roggero E, Bonin S., Stanta G. The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients. Radiol. Oncol., 2016: 50, 313-320.

57. Orteronel Switch Maintenance Thera in Metastatic Castration Resistant Prostate Cancer After First-Line

Docetaxel: A Mufticenter, Randomized, Double-Blindi Placebo-Controlled Trial (SAKK 08/1 1 ). Cathomas R, Crabb

SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, von Burg P, Kenner H, Hayoz S, Vilei SB, Rauch D,

Roggero E, Mohaupt MG, Bernhard J, Manetsch G, Gillessen S; Swiss Group for Clinical Cancer Research SAKK. Prostate. 2016

58. Muoio B., Pascale M., Roggero R. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature. Int J Biol Markers., 2018; 33(1 ): 10-21

59. Pascale M., Azinwi N.C., Marongiu B., Pesce G., Stoffel F., Roggero E. The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression. BMC Cancer, 2017; 17: 651.

60. Omlin A, Spahn M, Beyer J, Eberli D, Gillessen S, Jochum W, Kueng M, Nitzsche E, Rentsch CA, Roggero E, Schmid HP, Stenner F, Templeton AJ, Wild D, Wyler S, Zwahlen D, Cathomas R. Treatment of advanced prostate carcinoma — an international recommendatíon. Praxis. 2018 Sep; 107(1 9): 1043-1051.

61, Pereira Mestre R, Treglia G, Ferrari M, Pascale M, Mazzara C, Azinwi NC, Lladà A, Stathis A, Giovanella L,

Roggero E Correlation between PSA kinetics and PSMA PET/CT in prostate cancer_restaging: a meta-analysis..

62. R, Treglia G, Pereira Mestre R, Ferrari M, Bosetti DG, Pascale M, Oikonomou E, De Dosso S, Jermini F, Prior JO, A, Giovanella L, Roggero E. Radiolabeled choline versus PSMA PET/CT in prostate cancer restaging: a metaanalysis.. Am J Nucl Med Mol Imaging. 2019 Apri15;9(2):127-139.

63. Ferrari M, Mazzola B, Roggero E, D'Antonio E, Mestre R, Porcu G, Stoffel F, Renard J. Current evidence between hospital volume and perioperative outcome: prospective assessment of robotic radical prostatectomy safety profile in a regional center of medium annual caseload.. Can Urol Assoc J. 2021 Mar; 1 5(3): El 53-EI 59.